Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

(2015) I-K Park et al.   LEUKEMIA

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

(2015) C C Smith et al.   LEUKEMIA

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia

(2015) Michael R. Grunwald et al.   SEMINARS IN HEMATOLOGY

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

(2015) Melanie Janning et al.   Expert Review of Hematology

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

(2015) C. C. Smith et al.   Cancer Discovery

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies

(2015) Kristen Pettit et al.   Frontiers in Oncology

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

(2014) Keith W. Pratz et al.   CURRENT OPINION IN HEMATOLOGY

Targeting FLT3 to treat leukemia

(2014) Heiko Konig et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Inhibition of c-Kit by tyrosine kinase inhibitors

(2014) A. Galanis et al.   HAEMATOLOGICA

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

(2013) I. Ben-Batalla et al.   BLOOD

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

(2013) E. I. Zimmerman et al.   BLOOD

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Establishment of a bioluminescent imaging-based in vivo leukemia model by intra-bone marrow injection

(2012) MYOUNG WOO LEE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD